Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Many Likes Clear all
Terminated Phase 2 Interventional Results available

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

NCT00572156
View directory record Official record
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 19, 2026, 5:28 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

NCT03897205
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Imlifidase, Plasma Exchange
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 19, 2026, 5:28 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Radiofrequency Ablation: Treatment for Posterior Element Pain From Vertebral Compression Fractures

NCT03651804
View directory record Official record
Conditions
Vertebral Compression Fracture, Facet Joint Pain
Interventions
Radiofrequency ablation of the medial branch nerves, Non-steroidal anti-inflammatory drugs, Bisphosphonates, Acetaminophen, Physical therapy, Opioids
Procedure · Drug · Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 19, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

NCT01592552
View directory record Official record
Conditions
Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Sherman Oaks, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

NCT01179048
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
9,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
125
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 19, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 19, 2026, 5:28 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Tirzepatide, Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
141
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

NCT05903183
View directory record Official record
Conditions
Healthy
Interventions
IVX-A12, Placebo
Biological
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
10
States / cities
Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 19, 2026, 5:28 AM EDT
Enrolling by invitation Not applicable Interventional

Comparing Two Moral Injury Treatments

NCT07710521
View directory record Official record
Conditions
Moral Injury
Interventions
Acceptance and Commitment Therapy for Moral Injury (ACT-MI), Present Centered Therapy for Moral Injury (PCT-MI)
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 89 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 1 Interventional Results available

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

NCT00728936
View directory record Official record
Conditions
Hepatitis C
Interventions
IMO-2125, Saline placebo
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Aurora, Colorado • Marietta, Georgia • Novi, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

NCT01881230
View directory record Official record
Conditions
Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer, Triple-negative Metastatic Breast Cancer, Metastatic Breast Cancer
Interventions
nab-Paclitaxel, Carboplatin, Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
64
States / cities
Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

NCT02918279
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 17 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Meridian, Idaho • Baton Rouge, Louisiana • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 19, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

NCT05171972
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Recruiting Phase 1 Interventional

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

NCT07868354
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Tirzepatide, Zenagamtide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment

NCT03292705
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
PEP, CCI
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Pilot Study of Mothers and Babies Online in Home Visiting

NCT05714956
View directory record Official record
Conditions
Perinatal Depression
Interventions
Mothers and Babies Online (eMB)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Joliet, Illinois • Chariton, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 19, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional

Safer Still (Exploratory Project 3)

NCT06558409
View directory record Official record
Conditions
Suicide Prevention
Interventions
" Safer Still " Interactive Intervention, Enhanced Usual Care (EUC):
Behavioral · Other
Lead sponsor
Jeff Bridge
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material

NCT02267187
View directory record Official record
Conditions
Facial Injuries
Interventions
Fat Grafting, General Anesthesia, Coleman Cannulas, Tefla non-adherent gauze pad
Procedure · Drug · Device + 1 more
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 19, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional Results available

Binge Eating Liraglutide Intervention

NCT03279731
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
Drug
Lead sponsor
Kelly Allison
Other
Eligibility
21 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 19, 2026, 5:28 AM EDT
Not yet recruiting Not applicable Interventional

A Mobile Text Approach to Measurement and Feedback for Wraparound Care Coordination

NCT07300930
View directory record Official record
Conditions
Mental Health Services, Mobile Technologies, Technology Development
Interventions
SMARTwrap
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
8 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT

NCT05928156
View directory record Official record
Conditions
Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions
Myeloma Coach or CLL Coach Mobile App, Springboard Beyond Cancer informational website
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 19, 2026, 5:28 AM EDT